News & Updates

A single-pill combination that contains albendazole and ivermectin is superior to albendazole alone for treating Trichuris trichiura and hookworm infections, with similar safety profiles, according to data from a phase II/III trial.

Among patients with inflammatory bowel disease (IBD), treatment with Janus kinase inhibitors (JAKi) does not increase the risk of major adverse cardiovascular events (MACE) compared with tumour necrosis factor inhibitors (TNFi), according to a study presented at AIBD 2024.

First-line treatment with erlotinib, gefitinib, and osimertinib demonstrates safety and efficacy in patients with EGFR-mutated advanced nonsmall cell lung cancer (NSCLC), suggests a study.

People with gallstone disease are at higher risk of inflammatory bowel disease (IBD), regardless of other traditional risk factors, according to a study.

The use of noncigarette tobacco products is associated with distinctive cardiovascular outcomes, including stroke for cigar, heart failure for pipe, and total cardiovascular disease (CVD) for smokeless tobacco, as shown in a study.

RO7790121, an antibody against tumour necrosis factor-like ligand 1A (Anti-TL1A), helps improve the health-related quality of life (HR-QoL) for patients with moderately to severely active ulcerative colitis (UC), as shown in the phase IIb TUSCANY-2 trial.

Pregnant women with inflammatory bowel disease (IBD) who used antitumour necrosis factor (anti-TNF) therapy are at reduced risk of developing gestational diabetes mellitus (GDM), reports a study.